603334.SH
丰倍生物
SSE · Healthcare · Biotechnology · CN
CNY 31.22
−4.44%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +22.9%
- EBITDA
- +4.8%
- EBIT
- +1.7%
- Net income
- +1.8%
- EPS
- -0.5%
- Free cash flow
- +11.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026